Table of Content

1 Report Overview
1.1 Anti-Inflammatory Peptides Definition
1.2 Market by Type
1.2.1 Global Anti-Inflammatory Peptides Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Cardiovascular Diseases
1.2.3 Gastrointestinal Diseases
1.2.4 Dermatological Diseases
1.2.5 Neurological Diseases
1.2.6 Otorhino Diseases & Ophthalmological
1.2.7 Respiratory Diseases & Pulmonary
1.2.8 Renal Diseases
1.2.9 Rheumatological & Autoimmune Diseases
1.2.10 Transplantation
1.3 Market Segment by Application
1.3.1 Global Anti-Inflammatory Peptides Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Inflammatory Peptides Sales
2.1 Global Anti-Inflammatory Peptides Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Inflammatory Peptides Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Anti-Inflammatory Peptides Revenue by Region
2.3.1 Global Anti-Inflammatory Peptides Revenue by Region (2018-2023)
2.3.2 Global Anti-Inflammatory Peptides Revenue by Region (2024-2034)
2.4 Global Anti-Inflammatory Peptides Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Inflammatory Peptides Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Anti-Inflammatory Peptides Sales Quantity by Region
2.6.1 Global Anti-Inflammatory Peptides Sales Quantity by Region (2018-2023)
2.6.2 Global Anti-Inflammatory Peptides Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Inflammatory Peptides Sales Quantity by Manufacturers
3.1.1 Global Anti-Inflammatory Peptides Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Anti-Inflammatory Peptides Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Inflammatory Peptides Sales in 2024
3.2 Global Anti-Inflammatory Peptides Revenue by Manufacturers
3.2.1 Global Anti-Inflammatory Peptides Revenue by Manufacturers (2018-2023)
3.2.2 Global Anti-Inflammatory Peptides Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Inflammatory Peptides Revenue in 2024
3.3 Global Anti-Inflammatory Peptides Sales Price by Manufacturers
3.4 Global Key Players of Anti-Inflammatory Peptides, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Inflammatory Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Inflammatory Peptides, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Inflammatory Peptides, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Inflammatory Peptides, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Inflammatory Peptides Sales Quantity by Type
4.1.1 Global Anti-Inflammatory Peptides Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Anti-Inflammatory Peptides Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Inflammatory Peptides Revenue by Type
4.2.1 Global Anti-Inflammatory Peptides Historical Revenue by Type (2018-2023)
4.2.2 Global Anti-Inflammatory Peptides Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Inflammatory Peptides Price by Type
4.3.1 Global Anti-Inflammatory Peptides Price by Type (2018-2023)
4.3.2 Global Anti-Inflammatory Peptides Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Inflammatory Peptides Sales Quantity by Application
5.1.1 Global Anti-Inflammatory Peptides Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Anti-Inflammatory Peptides Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Inflammatory Peptides Revenue by Application
5.2.1 Global Anti-Inflammatory Peptides Historical Revenue by Application (2018-2023)
5.2.2 Global Anti-Inflammatory Peptides Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Inflammatory Peptides Price by Application
5.3.1 Global Anti-Inflammatory Peptides Price by Application (2018-2023)
5.3.2 Global Anti-Inflammatory Peptides Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Inflammatory Peptides Sales by Company
6.1.1 North America Anti-Inflammatory Peptides Revenue by Company (2018-2023)
6.1.2 North America Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023)
6.2 North America Anti-Inflammatory Peptides Market Size by Type
6.2.1 North America Anti-Inflammatory Peptides Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Inflammatory Peptides Revenue by Type (2018-2034)
6.3 North America Anti-Inflammatory Peptides Market Size by Application
6.3.1 North America Anti-Inflammatory Peptides Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Inflammatory Peptides Revenue by Application (2018-2034)
6.4 North America Anti-Inflammatory Peptides Market Size by Country
6.4.1 North America Anti-Inflammatory Peptides Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Anti-Inflammatory Peptides Revenue by Country (2018-2034)
6.4.3 North America Anti-Inflammatory Peptides Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-Inflammatory Peptides Sales by Company
7.1.1 Europe Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023)
7.1.2 Europe Anti-Inflammatory Peptides Revenue by Company (2018-2023)
7.2 Europe Anti-Inflammatory Peptides Market Size by Type
7.2.1 Europe Anti-Inflammatory Peptides Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Inflammatory Peptides Revenue by Type (2018-2034)
7.3 Europe Anti-Inflammatory Peptides Market Size by Application
7.3.1 Europe Anti-Inflammatory Peptides Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Inflammatory Peptides Revenue by Application (2018-2034)
7.4 Europe Anti-Inflammatory Peptides Market Size by Country
7.4.1 Europe Anti-Inflammatory Peptides Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Anti-Inflammatory Peptides Revenue by Country (2018-2034)
7.4.3 Europe Anti-Inflammatory Peptides Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Inflammatory Peptides Sales by Company
8.1.1 China Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023)
8.1.2 China Anti-Inflammatory Peptides Revenue by Company (2018-2023)
8.2 China Anti-Inflammatory Peptides Market Size by Type
8.2.1 China Anti-Inflammatory Peptides Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Inflammatory Peptides Revenue by Type (2018-2034)
8.3 China Anti-Inflammatory Peptides Market Size by Application
8.3.1 China Anti-Inflammatory Peptides Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Inflammatory Peptides Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Inflammatory Peptides Sales by Company
9.1.1 APAC Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023)
9.1.2 APAC Anti-Inflammatory Peptides Revenue by Company (2018-2023)
9.2 APAC Anti-Inflammatory Peptides Market Size by Type
9.2.1 APAC Anti-Inflammatory Peptides Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Inflammatory Peptides Revenue by Type (2018-2034)
9.3 APAC Anti-Inflammatory Peptides Market Size by Application
9.3.1 APAC Anti-Inflammatory Peptides Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Inflammatory Peptides Revenue by Application (2018-2034)
9.4 APAC Anti-Inflammatory Peptides Market Size by Region
9.4.1 APAC Anti-Inflammatory Peptides Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Anti-Inflammatory Peptides Revenue by Region (2018-2034)
9.4.3 APAC Anti-Inflammatory Peptides Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Anti-Inflammatory Peptides Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Inflammatory Peptides Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Inflammatory Peptides Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Mylan Pharmaceuticals
11.1.1 Mylan Pharmaceuticals Company Information
11.1.2 Mylan Pharmaceuticals Overview
11.1.3 Mylan Pharmaceuticals Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Mylan Pharmaceuticals Anti-Inflammatory Peptides Products and Services
11.1.5 Mylan Pharmaceuticals Anti-Inflammatory Peptides SWOT Analysis
11.1.6 Mylan Pharmaceuticals Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Information
11.2.2 Novartis AG Overview
11.2.3 Novartis AG Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Novartis AG Anti-Inflammatory Peptides Products and Services
11.2.5 Novartis AG Anti-Inflammatory Peptides SWOT Analysis
11.2.6 Novartis AG Recent Developments
11.3 Rogne Bioscience
11.3.1 Rogne Bioscience Company Information
11.3.2 Rogne Bioscience Overview
11.3.3 Rogne Bioscience Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Rogne Bioscience Anti-Inflammatory Peptides Products and Services
11.3.5 Rogne Bioscience Anti-Inflammatory Peptides SWOT Analysis
11.3.6 Rogne Bioscience Recent Developments
11.4 Merck Serono
11.4.1 Merck Serono Company Information
11.4.2 Merck Serono Overview
11.4.3 Merck Serono Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Merck Serono Anti-Inflammatory Peptides Products and Services
11.4.5 Merck Serono Anti-Inflammatory Peptides SWOT Analysis
11.4.6 Merck Serono Recent Developments
11.5 F4 Pharma
11.5.1 F4 Pharma Company Information
11.5.2 F4 Pharma Overview
11.5.3 F4 Pharma Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 F4 Pharma Anti-Inflammatory Peptides Products and Services
11.5.5 F4 Pharma Anti-Inflammatory Peptides SWOT Analysis
11.5.6 F4 Pharma Recent Developments
11.6 Araim Pharmaceuticals, Inc.
11.6.1 Araim Pharmaceuticals, Inc. Company Information
11.6.2 Araim Pharmaceuticals, Inc. Overview
11.6.3 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Products and Services
11.6.5 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides SWOT Analysis
11.6.6 Araim Pharmaceuticals, Inc. Recent Developments
11.7 Digna Biotech
11.7.1 Digna Biotech Company Information
11.7.2 Digna Biotech Overview
11.7.3 Digna Biotech Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Digna Biotech Anti-Inflammatory Peptides Products and Services
11.7.5 Digna Biotech Anti-Inflammatory Peptides SWOT Analysis
11.7.6 Digna Biotech Recent Developments
11.8 Abbvie Corporation
11.8.1 Abbvie Corporation Company Information
11.8.2 Abbvie Corporation Overview
11.8.3 Abbvie Corporation Anti-Inflammatory Peptides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Abbvie Corporation Anti-Inflammatory Peptides Products and Services
11.8.5 Abbvie Corporation Anti-Inflammatory Peptides SWOT Analysis
11.8.6 Abbvie Corporation Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Inflammatory Peptides Value Chain Analysis
12.2 Anti-Inflammatory Peptides Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Inflammatory Peptides Production Mode & Process
12.4 Anti-Inflammatory Peptides Sales and Marketing
12.4.1 Anti-Inflammatory Peptides Sales Channels
12.4.2 Anti-Inflammatory Peptides Distributors
12.5 Anti-Inflammatory Peptides Customers
13 Market Dynamics
13.1 Anti-Inflammatory Peptides Industry Trends
13.2 Anti-Inflammatory Peptides Market Drivers
13.3 Anti-Inflammatory Peptides Market Challenges
13.4 Anti-Inflammatory Peptides Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Inflammatory Peptides Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Cardiovascular Diseases
Table 3. Major Manufacturers of Gastrointestinal Diseases
Table 4. Major Manufacturers of Dermatological Diseases
Table 5. Major Manufacturers of Neurological Diseases
Table 6. Major Manufacturers of Otorhino Diseases & Ophthalmological
Table 7. Major Manufacturers of Respiratory Diseases & Pulmonary
Table 8. Major Manufacturers of Renal Diseases
Table 9. Major Manufacturers of Rheumatological & Autoimmune Diseases
Table 10. Major Manufacturers of Transplantation
Table 11. Global Anti-Inflammatory Peptides Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 12. Global Anti-Inflammatory Peptides Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 13. Global Anti-Inflammatory Peptides Revenue by Region (2018-2023) & (US$ Million)
Table 14. Global Anti-Inflammatory Peptides Revenue Market Share by Region (2018-2023)
Table 15. Global Anti-Inflammatory Peptides Revenue by Region (2024-2034) & (US$ Million)
Table 16. Global Anti-Inflammatory Peptides Revenue Market Share by Region (2024-2034)
Table 17. Global Anti-Inflammatory Peptides Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 18. Global Anti-Inflammatory Peptides Sales by Region (2018-2023) & (K Units)
Table 19. Global Anti-Inflammatory Peptides Sales Market Share by Region (2018-2023)
Table 20. Global Anti-Inflammatory Peptides Sales by Region (2024-2034) & (K Units)
Table 21. Global Anti-Inflammatory Peptides Sales Market Share by Region (2024-2034)
Table 22. Global Anti-Inflammatory Peptides Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 23. Global Anti-Inflammatory Peptides Sales Quantity Share by Manufacturers (2018-2023)
Table 24. Global Anti-Inflammatory Peptides Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 25. Global Anti-Inflammatory Peptides Revenue Share by Manufacturers (2018-2023)
Table 26. Global Anti-Inflammatory Peptides Price by Manufacturers 2018-2023 (USD/Unit)
Table 27. Global Key Players of Anti-Inflammatory Peptides, Industry Ranking, 2021 VS 2024
Table 28. Global Anti-Inflammatory Peptides Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 29. Global Anti-Inflammatory Peptides by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Inflammatory Peptides as of 2024)
Table 30. Global Key Manufacturers of Anti-Inflammatory Peptides, Manufacturing Base Distribution and Headquarters
Table 31. Global Key Manufacturers of Anti-Inflammatory Peptides, Product Offered and Application
Table 32. Global Key Manufacturers of Anti-Inflammatory Peptides, Date of Enter into This Industry
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Anti-Inflammatory Peptides Sales Quantity by Type (2018-2023) & (K Units)
Table 35. Global Anti-Inflammatory Peptides Sales Quantity by Type (2024-2034) & (K Units)
Table 36. Global Anti-Inflammatory Peptides Sales Quantity Share by Type (2018-2023)
Table 37. Global Anti-Inflammatory Peptides Sales Quantity Share by Type (2024-2034)
Table 38. Global Anti-Inflammatory Peptides Revenue by Type (2018-2023) & (US$ Million)
Table 39. Global Anti-Inflammatory Peptides Revenue by Type (2024-2034) & (US$ Million)
Table 40. Global Anti-Inflammatory Peptides Revenue Share by Type (2018-2023)
Table 41. Global Anti-Inflammatory Peptides Revenue Share by Type (2024-2034)
Table 42. Anti-Inflammatory Peptides Price by Type (2018-2023) & (USD/Unit)
Table 43. Global Anti-Inflammatory Peptides Price Forecast by Type (2024-2034) & (USD/Unit)
Table 44. Global Anti-Inflammatory Peptides Sales Quantity by Application (2018-2023) & (K Units)
Table 45. Global Anti-Inflammatory Peptides Sales Quantity by Application (2024-2034) & (K Units)
Table 46. Global Anti-Inflammatory Peptides Sales Quantity Share by Application (2018-2023)
Table 47. Global Anti-Inflammatory Peptides Sales Quantity Share by Application (2024-2034)
Table 48. Global Anti-Inflammatory Peptides Revenue by Application (2018-2023) & (US$ Million)
Table 49. Global Anti-Inflammatory Peptides Revenue by Application (2024-2034) & (US$ Million)
Table 50. Global Anti-Inflammatory Peptides Revenue Share by Application (2018-2023)
Table 51. Global Anti-Inflammatory Peptides Revenue Share by Application (2024-2034)
Table 52. Anti-Inflammatory Peptides Price by Application (2018-2023) & (USD/Unit)
Table 53. Global Anti-Inflammatory Peptides Price Forecast by Application (2024-2034) & (USD/Unit)
Table 54. North America Anti-Inflammatory Peptides Revenue by Company (2018-2023) & (US$ Million)
Table 55. North America Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023) & (K Units)
Table 56. North America Anti-Inflammatory Peptides Sales Quantity by Type (2018-2023) & (K Units)
Table 57. North America Anti-Inflammatory Peptides Sales Quantity by Type (2024-2034) & (K Units)
Table 58. North America Anti-Inflammatory Peptides Revenue by Type (2018-2023) & (US$ Million)
Table 59. North America Anti-Inflammatory Peptides Revenue by Type (2024-2034) & (US$ Million)
Table 60. North America Anti-Inflammatory Peptides Sales Quantity by Application (2018-2023) & (K Units)
Table 61. North America Anti-Inflammatory Peptides Sales Quantity by Application (2024-2034) & (K Units)
Table 62. North America Anti-Inflammatory Peptides Revenue by Application (2018-2023) & (US$ Million)
Table 63. North America Anti-Inflammatory Peptides Revenue by Application (2024-2034) & (US$ Million)
Table 64. North America Anti-Inflammatory Peptides Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 65. North America Anti-Inflammatory Peptides Revenue by Country (2018-2023) & (US$ Million)
Table 66. North America Anti-Inflammatory Peptides Revenue by Country (2024-2034) & (US$ Million)
Table 67. North America Anti-Inflammatory Peptides Sales Quantity by Country (2018-2023) & (K Units)
Table 68. North America Anti-Inflammatory Peptides Sales Quantity by Country (2024-2034) & (K Units)
Table 69. Europe Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023) & (K Units)
Table 70. Europe Anti-Inflammatory Peptides Revenue by Company (2018-2023) & (US$ Million)
Table 71. Europe Anti-Inflammatory Peptides Sales Quantity by Type (2018-2023) & (K Units)
Table 72. Europe Anti-Inflammatory Peptides Sales Quantity by Type (2024-2034) & (K Units)
Table 73. Europe Anti-Inflammatory Peptides Revenue by Type (2018-2023) & (US$ Million)
Table 74. Europe Anti-Inflammatory Peptides Revenue by Type (2024-2034) & (US$ Million)
Table 75. Europe Anti-Inflammatory Peptides Sales Quantity by Application (2018-2023) & (K Units)
Table 76. Europe Anti-Inflammatory Peptides Sales Quantity by Application (2024-2034) & (K Units)
Table 77. Europe Anti-Inflammatory Peptides Revenue by Application (2018-2023) & (US$ Million)
Table 78. Europe Anti-Inflammatory Peptides Revenue by Application (2024-2034) & (US$ Million)
Table 79. Europe Anti-Inflammatory Peptides Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 80. Europe Anti-Inflammatory Peptides Revenue by Country (2018-2023) & (US$ Million)
Table 81. Europe Anti-Inflammatory Peptides Revenue by Country (2024-2034) & (US$ Million)
Table 82. Europe Anti-Inflammatory Peptides Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Anti-Inflammatory Peptides Sales Quantity by Country (2024-2034) & (K Units)
Table 84. China Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023) & (K Units)
Table 85. China Anti-Inflammatory Peptides Revenue by Company (2018-2023) & (US$ Million)
Table 86. China Anti-Inflammatory Peptides Sales Quantity by Type (2018-2023) & (K Units)
Table 87. China Anti-Inflammatory Peptides Sales Quantity by Type (2024-2034) & (K Units)
Table 88. China Anti-Inflammatory Peptides Revenue by Type (2018-2023) & (US$ Million)
Table 89. China Anti-Inflammatory Peptides Revenue by Type (2024-2034) & (US$ Million)
Table 90. China Anti-Inflammatory Peptides Sales Quantity by Application (2018-2023) & (K Units)
Table 91. China Anti-Inflammatory Peptides Sales Quantity by Application (2024-2034) & (K Units)
Table 92. China Anti-Inflammatory Peptides Revenue by Application (2018-2023) & (US$ Million)
Table 93. China Anti-Inflammatory Peptides Revenue by Application (2024-2034) & (US$ Million)
Table 94. APAC Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023) & (K Units)
Table 95. APAC Anti-Inflammatory Peptides Revenue by Company (2018-2023) & (US$ Million)
Table 96. APAC Anti-Inflammatory Peptides Sales Quantity by Type (2018-2023) & (K Units)
Table 97. APAC Anti-Inflammatory Peptides Sales Quantity by Type (2024-2034) & (K Units)
Table 98. APAC Anti-Inflammatory Peptides Revenue by Type (2018-2023) & (US$ Million)
Table 99. APAC Anti-Inflammatory Peptides Revenue by Type (2024-2034) & (US$ Million)
Table 100. APAC Anti-Inflammatory Peptides Sales Quantity by Application (2018-2023) & (K Units)
Table 101. APAC Anti-Inflammatory Peptides Sales Quantity by Application (2024-2034) & (K Units)
Table 102. APAC Anti-Inflammatory Peptides Revenue by Application (2018-2023) & (US$ Million)
Table 103. APAC Anti-Inflammatory Peptides Revenue by Application (2024-2034) & (US$ Million)
Table 104. APAC Anti-Inflammatory Peptides Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 105. APAC Anti-Inflammatory Peptides Revenue by Region (2018-2023) & (US$ Million)
Table 106. APAC Anti-Inflammatory Peptides Revenue by Region (2024-2034) & (US$ Million)
Table 107. APAC Anti-Inflammatory Peptides Sales Quantity by Region (2018-2023) & (K Units)
Table 108. APAC Anti-Inflammatory Peptides Sales Quantity by Region (2024-2034) & (K Units)
Table 109. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Company (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Company (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Type (2018-2023) & (K Units)
Table 112. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Type (2024-2034) & (K Units)
Table 113. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Type (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Type (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Application (2024-2034) & (K Units)
Table 117. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Application (2018-2023) & (US$ Million)
Table 118. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Application (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 120. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Country (2018-2023) & (US$ Million)
Table 121. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue by Country (2024-2034) & (US$ Million)
Table 122. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Country (2018-2023) & (K Units)
Table 123. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity by Country (2024-2034) & (K Units)
Table 124. Mylan Pharmaceuticals Company Information
Table 125. Mylan Pharmaceuticals Description and Overview
Table 126. Mylan Pharmaceuticals Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 127. Mylan Pharmaceuticals Anti-Inflammatory Peptides Product and Services
Table 128. Mylan Pharmaceuticals Anti-Inflammatory Peptides SWOT Analysis
Table 129. Mylan Pharmaceuticals Recent Developments
Table 130. Novartis AG Company Information
Table 131. Novartis AG Description and Overview
Table 132. Novartis AG Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 133. Novartis AG Anti-Inflammatory Peptides Product and Services
Table 134. Novartis AG Anti-Inflammatory Peptides SWOT Analysis
Table 135. Novartis AG Recent Developments
Table 136. Rogne Bioscience Company Information
Table 137. Rogne Bioscience Description and Overview
Table 138. Rogne Bioscience Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 139. Rogne Bioscience Anti-Inflammatory Peptides Product and Services
Table 140. Rogne Bioscience Anti-Inflammatory Peptides SWOT Analysis
Table 141. Rogne Bioscience Recent Developments
Table 142. Merck Serono Company Information
Table 143. Merck Serono Description and Overview
Table 144. Merck Serono Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 145. Merck Serono Anti-Inflammatory Peptides Product and Services
Table 146. Merck Serono Anti-Inflammatory Peptides SWOT Analysis
Table 147. Merck Serono Recent Developments
Table 148. F4 Pharma Company Information
Table 149. F4 Pharma Description and Overview
Table 150. F4 Pharma Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 151. F4 Pharma Anti-Inflammatory Peptides Product and Services
Table 152. F4 Pharma Anti-Inflammatory Peptides SWOT Analysis
Table 153. F4 Pharma Recent Developments
Table 154. Araim Pharmaceuticals, Inc. Company Information
Table 155. Araim Pharmaceuticals, Inc. Description and Overview
Table 156. Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 157. Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Product and Services
Table 158. Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides SWOT Analysis
Table 159. Araim Pharmaceuticals, Inc. Recent Developments
Table 160. Digna Biotech Company Information
Table 161. Digna Biotech Description and Overview
Table 162. Digna Biotech Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 163. Digna Biotech Anti-Inflammatory Peptides Product and Services
Table 164. Digna Biotech Anti-Inflammatory Peptides SWOT Analysis
Table 165. Digna Biotech Recent Developments
Table 166. Abbvie Corporation Company Information
Table 167. Abbvie Corporation Description and Overview
Table 168. Abbvie Corporation Anti-Inflammatory Peptides Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 169. Abbvie Corporation Anti-Inflammatory Peptides Product and Services
Table 170. Abbvie Corporation Anti-Inflammatory Peptides SWOT Analysis
Table 171. Abbvie Corporation Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Anti-Inflammatory Peptides Distributors List
Table 175. Anti-Inflammatory Peptides Customers List
Table 176. Anti-Inflammatory Peptides Market Trends
Table 177. Anti-Inflammatory Peptides Market Drivers
Table 178. Anti-Inflammatory Peptides Market Challenges
Table 179. Anti-Inflammatory Peptides Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Inflammatory Peptides Product Picture
Figure 2. Global Anti-Inflammatory Peptides Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Anti-Inflammatory Peptides Market Share by Type in 2024 & 2034
Figure 4. Cardiovascular Diseases Product Picture
Figure 5. Gastrointestinal Diseases Product Picture
Figure 6. Dermatological Diseases Product Picture
Figure 7. Neurological Diseases Product Picture
Figure 8. Otorhino Diseases & Ophthalmological Product Picture
Figure 9. Respiratory Diseases & Pulmonary Product Picture
Figure 10. Renal Diseases Product Picture
Figure 11. Rheumatological & Autoimmune Diseases Product Picture
Figure 12. Transplantation Product Picture
Figure 13. Global Anti-Inflammatory Peptides Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 14. Global Anti-Inflammatory Peptides Market Share by Application in 2024 & 2034
Figure 15. Hospital Use
Figure 16. Clinic Use
Figure 17. Household
Figure 18. Other
Figure 19. Anti-Inflammatory Peptides Report Years Considered
Figure 20. Global Anti-Inflammatory Peptides Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 21. Global Anti-Inflammatory Peptides Revenue 2018-2034 (US$ Million)
Figure 22. Global Anti-Inflammatory Peptides Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 23. Global Anti-Inflammatory Peptides Sales Quantity 2018-2034 (K Units)
Figure 24. Global Anti-Inflammatory Peptides Sales Quantity Market Share by Region (2018-2023)
Figure 25. Global Anti-Inflammatory Peptides Sales Quantity Market Share by Region (2024-2034)
Figure 26. North America Anti-Inflammatory Peptides Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. North America Anti-Inflammatory Peptides Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Europe Anti-Inflammatory Peptides Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Europe Anti-Inflammatory Peptides Revenue YoY (2018-2034) & (US$ Million)
Figure 30. China Anti-Inflammatory Peptides Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. China Anti-Inflammatory Peptides Revenue YoY (2018-2034) & (US$ Million)
Figure 32. APAC Anti-Inflammatory Peptides Sales Quantity YoY (2018-2034) & (K Units)
Figure 33. APAC Anti-Inflammatory Peptides Revenue YoY (2018-2034) & (US$ Million)
Figure 34. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity YoY (2018-2034) & (K Units)
Figure 35. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue YoY (2018-2034) & (US$ Million)
Figure 36. The Top 10 and Top 5 Players Market Share by Anti-Inflammatory Peptides Sales Quantity in 2024
Figure 37. The Top 10 and Top 5 Players Market Share by Anti-Inflammatory Peptides Revenue in 2024
Figure 38. Anti-Inflammatory Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 39. Global Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
Figure 40. Global Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
Figure 41. Global Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
Figure 42. Global Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
Figure 43. North America Anti-Inflammatory Peptides Revenue Market Share by Company in 2024
Figure 44. North America Anti-Inflammatory Peptides Sales Quantity Market Share by Company in 2024
Figure 45. North America Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
Figure 46. North America Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
Figure 47. North America Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
Figure 48. North America Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
Figure 49. North America Anti-Inflammatory Peptides Revenue Share by Country (2018-2034)
Figure 50. North America Anti-Inflammatory Peptides Sales Quantity Share by Country (2018-2034)
Figure 51. U.S. Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 52. Canada Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 53. Europe Anti-Inflammatory Peptides Sales Quantity Market Share by Company in 2024
Figure 54. Europe Anti-Inflammatory Peptides Revenue Market Share by Company in 2024
Figure 55. Europe Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
Figure 56. Europe Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
Figure 57. Europe Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
Figure 58. Europe Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
Figure 59. Europe Anti-Inflammatory Peptides Revenue Share by Country (2018-2034)
Figure 60. Europe Anti-Inflammatory Peptides Sales Quantity Share by Country (2018-2034)
Figure 61. Germany Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 62. France Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 63. U.K. Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 64. Italy Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 65. Russia Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 66. China Anti-Inflammatory Peptides Sales Quantity Market Share by Company in 2024
Figure 67. China Anti-Inflammatory Peptides Revenue Market Share by Company in 2024
Figure 68. China Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
Figure 69. China Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
Figure 70. China Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
Figure 71. China Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
Figure 72. APAC Anti-Inflammatory Peptides Sales Quantity Market Share by Company in 2024
Figure 73. APAC Anti-Inflammatory Peptides Revenue Market Share by Company in 2024
Figure 74. APAC Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
Figure 75. APAC Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
Figure 76. APAC Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
Figure 77. APAC Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
Figure 78. APAC Anti-Inflammatory Peptides Revenue Share by Region (2018-2034)
Figure 79. APAC Anti-Inflammatory Peptides Sales Quantity Share by Region (2018-2034)
Figure 80. Japan Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 81. South Korea Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 82. China Taiwan Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 83. Southeast Asia Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 84. India Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 85. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity Market Share by Company in 2024
Figure 86. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue Market Share by Company in 2024
Figure 87. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity Market Share by Type (2018-2034)
Figure 88. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue Market Share by Type (2018-2034)
Figure 89. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity Market Share by Application (2018-2034)
Figure 90. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue Market Share by Application (2018-2034)
Figure 91. Middle East, Africa and Latin America Anti-Inflammatory Peptides Sales Quantity Share by Country (2018-2034)
Figure 92. Middle East, Africa and Latin America Anti-Inflammatory Peptides Revenue Share by Country (2018-2034)
Figure 93. Brazil Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 94. Mexico Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 95. Turkey Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 96. Israel Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 97. GCC Countries Anti-Inflammatory Peptides Revenue (2018-2034) & (US$ Million)
Figure 98. Anti-Inflammatory Peptides Value Chain
Figure 99. Anti-Inflammatory Peptides Production Process
Figure 100. Channels of Distribution (Direct Vs Distribution)
Figure 101. Distributors Profiles
Figure 102. Bottom-up and Top-down Approaches for This Report
Figure 103. Data Triangulation
Figure 104. Key Executives Interviewed